Anjarium Biosciences develops synthetic, enzymatically produced linear double-stranded DNA with customizable hairpin-ended structures to enhance the production of gene therapies. Their technology addresses the challenges of traditional plasmid DNA by providing faster production times, higher purity, and scalable solutions for various therapeutic applications.
Funding
$60.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFounders
Product
Problem
Traditional plasmid DNA production for gene therapies faces challenges such as slow production times, potential impurities from bacterial sequences, and limitations in customizing DNA constructs for specific therapeutic applications. These limitations can hinder the development and delivery of advanced genetic medicines.
Solution
Anjarium Biosciences develops and manufactures synthetic, enzymatically produced linear double-stranded DNA with customizable hairpin-ended structures, offering a superior alternative to plasmid DNA for cell and gene therapy applications. Their cell-free platform enables the creation of pure, customizable, and flexible synthetic DNA constructs, addressing the limitations of traditional methods. This technology facilitates faster production, higher purity, and scalable solutions for various therapeutic modalities, accelerating the discovery and delivery cycle of new and evolving genetic medicines.
Target Audience
Anjarium's primary customers are researchers and manufacturers in the cell and gene therapy field, including those involved in AAV, mRNA, and lentiviral vector production, as well as those developing novel gene therapies.
Features
- Enzymatic DNA synthesis for cleaner, high-fidelity, hairpin-ended, linear, double-stranded DNA products.
- Customizable terminal DNA structures and complex transgene sequences.
- Scalable production from microgram to multigram quantities.
- Elimination of bacterial sequences, reducing the risk of unwanted elements and DNA backbone components.
- Stable poly-A tails up to 140+ nucleotides for mRNA production.
- Design and manufacturing services for custom constructs.
- Anion exchange chromatography resin for lentiviral vector purification, achieving higher virus recovery rates and enhanced purity.